Efficacy and safety of TiNO-coated stents versus drug-eluting coronary stents. Systematic literature review and meta-analysis.

Frederic C. Daoud, MD, MSc[a], Louis Létinier, MD, MSc[a], Nicholas Moore, MD, PhD[a], Pierre Coste, MD[b], Pasi P. Karjalainen, MD, PhD[c]

Short title: TiNO-coated stents *versus* DES meta-analysis

Affiliations

[a] Univ. Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France

[b] Coronary Care Unit, Cardiologic Hospital, University of Bordeaux, Pessac, France

[c] Cardiac unit, Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland

Address for correspondence

Frederic C. Daoud, M.D., M.Sc.
orcid.org/0000-0002-0469-9723
Université de Bordeaux
Unité de Pharmacologie clinique
INSERM U1219 Bordeaux Population Health Center
Bâtiment 1A, 1er étage, Case 36
146 rue Léo Saignat
33076 Bordeaux Cedex, France
Tel. +33 (0)5 57 57 15 60, Fax +33 (0)5 57 57 46 71 06
E-mail: frederic.daoud-pineau@u-bordeaux.fr

Manuscript file word count: 5,831

Figures: 6

Tables: 2

Abstract word count: 296

Abstract

Objectives: To compare clinical outcomes after percutaneous coronary intervention (PCI) using titanium-nitride-oxide coated stents (TiNOS) versus drug-eluting stents (DES) in coronary artery disease (CAD) including acute coronary syndrome (ACS).

Design: Prospective systematic literature (SLR) conducted according to PRISMA with Medline, Embase, Cochrane, Web of Science were searched in March 2018 and updated.

Setting: Interventional cardiology.

Participants: Patients with CAD, including ACS, requiring PCI.

Interventions: All prospective randomized controlled trials (RCTs) that compared clinical outcomes after PCI with DES versus TiNOS.

Outcome measures: The pooled risk ratios (RR), TiNOS over DES, with 95% confidence intervals (CI) are computed for device-oriented Major Adverse Cardiac Events (MACE), non-fatal myocardial infarction (MI), cardiac death (CD), clinically driven target lesion revascularization (TLR), as well as probable or definite stent thrombosis (ST) after one- to five-year after PCI. Pooled RRs are stratified according to baseline ACS versus other CAD. Sensitivity analysis (SA) and certainty of the evidence are rated per GRADE.

Results: Five RCTs are eligible with 1,855 patients with TiNOS versus 1,363 with DES at 1-year follow-up and 783 versus 771 at 5-year. Three RCTs treated patients with ACS only. One-year RRs in ACS are: MACE 0.93 [0.72, 1.20], MI 0.48 [0.31, 0.73], CD 0.66 [0.33, 1.31], TLR 1.55 [1.10, 2.19] and ST 0.35 [0.20, 0.64]. One-year MACE, MI, and ST are robust to SA. The certainty of the evidence is high in MACE, moderate in MI, and low or very low in the other endpoints. There are too few observations to conclude about other CAD and 5-year outcomes.

Conclusions: A similar risk of MACE is found in TiNOS and DES, with potentially fewer MI and ST but more TLR in TiNOS. Five-year interim results are consistent with 1-year conclusions. TiNOS are safe and effective in ACS.

Registration: PROSPERO CRD42018090622

59 **Strengths and limitations of this study**

60 - Strengths:

61 o The level of certainty of the evidence is high for the primary endpoint at one-year

62 follow-up in patients treated for acute coronary syndrome.

63 o The primary endpoint and critical secondary endpoints are robust to sensitivity

64 analysis.

65 - Limitations:

66 o Outcomes in patients treated for chronic coronary artery disease cannot be

67 analyzed.

68 o The level of certainty of the evidence of secondary endpoints is moderate or low.

69 o Analysis of five-year outcomes is still at an interim stage.

70

71

72 **Objectives**

73 Percutaneous coronary interventions (PCI) with drug-eluting stents (DES) is the standard of care
74 in Coronary Artery Disease (CAD), including Acute Coronary Syndrome (ACS).[1-6] mTOR
75 inhibitors such as everolimus and paclitaxel have been the main drug types used on stents to
76 inhibit post-stenting restenosis.[7-9] Their side effect is the increased risk of stent thrombosis (ST),
77 requiring prolonged Dual AntiPlatelet Therapy (DAPT) with its own risk of complications.[10,11]
78 Titanium-nitride-oxide coated coronary stents (TiNOS), also designated "bioactive stents" (BAS)
79 have a pharmacologically inactive, non-absorbable coating. Preclinical data has shown less
80 neointimal hyperplasia with TiNOS than with bare-metal stents (BMS).[12,13,14]
81 Several trials comparing TiNOS with DES have been conducted but no systematic review of that
82 evidence has been published so far.

83

84 **Participants – Interventions - Outcome measures**

85 The question was specified using the PICOS framework[15]: **P**atients presented CAD including
86 ACS. **I**ntervention was PCI using TiNOS. **C**omparator was PCI using DES. **O**utcomes were the
87 device-oriented Major Adverse Cardiac Events (MACE) and the components of that composiste
88 i.e., Cardiac death (CD), recurrent myocardial infarction (MI), and clinically driven target lesion
89 revascularization (TLR). Probable or definite ST, and all-cause mortality ("total death": TD)
90 were also analyzed. Outcomes were assessed at 1-year and 5-year follow-ups. **S**tudy methods
91 were prospective randomized controlled clinical trials (RCTs).

92

93 **Methods**

This systematic literature review (SLR) is the first to compare the efficacy and safety of TiNOS *versus* DES in CAD. It was designed and conducted according to methods described in the Cochrane Handbook with the use of "Grading of Recommendations Assessment, Development and Evaluation" (GRADE). The protocol was registered in PROSPERO (CRD4201809062) before initiation. It is reported according to "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA).[16-18]

Data recording and the meta-analysis were conducted in RevMan 5.3 (Review Manager Version 5.3 software. Copenhagen, Denmark: The Nordic Cochrane Centre, 2014). The certainty of evidence according was rated with GRADEpro GDT software 2020 on-line version, (https://gradepro.org). Additional analyses were performed in STATA 16 (StataCorp LP, College Station, Tx, USA) using the metan and metaprop packages.

Data sources

MEDLINE, EMBASE, the Cochrane Library, and Web of Science (WoS) electronic databases, were queried on March 8, 2018, using their search engines. The search terms were: *((bioactive OR (Titanium AND nitride AND oxide) OR TiNO OR TNO OR BAS) AND stent) AND (DES OR (drug AND eluting AND stent)) AND (RCT OR ((randomized OR randomised) AND controlled AND trial))*. No exclusion filter was applied related to language, country, year, or any other aspect. The websites of AHA, TCT, ESC, EuroPCR, and clinicaltrials.gov were also searched. The queries were updated on July 22, 2020, when all initially identified RCTs were published to retrieve new evidence if any, from RCTs meeting the PICOS specifications of this SLR.

The downloaded record files were imported and pooled and sifted in EndNote X8 (Clarivate Analytics, Philadelphia, PA, USA). One reference only was selected when duplicates were

identified. When differerent references concerned the same study, their information was pooled using the citation of the most recent one. Full articles were reviewed for all references.

Study selection and Data extraction

Two reviewers (FD and LL) performed independently the following steps: (1)Exhaustive reference screening, (2)Reference classification according to the inclusion and exclusion criteria, (3)Extraction of study methods, (4)Patient baseline data, (5)Treatment data and results of each eligible RCT, (6)Individual eligible RCT risk of bias rating, (7)Assessment of the certainty of the evidence for each outcome variable according to GRADE. The results were recorded in RevMan 5.3 file.

Differences were adjudicated by a third reviewer (NM). The similarity of the definitions of endpoints across the RCTs was discussed with one investigator (PK). The risk of bias of individual RCTs was rated according to the criteria proposed by the Cochrane Collaboration with operator blinding as a separate item.

The screened studies were included if they met the following criteria: First-hand clinical evidence with prospective inclusion; patients with CAD treated with coronary PCI; implantation of either TiNOS or DES after the random allocation of the stent type; target outcomes reported at 1-year and/or 5-year follow-up; the outcomes reported as the number of patients who were included along with the number or proportion of them who presented an event of interest.

Studies were ruled out if any of the study selection criteria were not met or if IRB/ethics committee approval and patient informed consent were not explicitly required.

138 The term ACS referred to patients who presented at baseline with ST-elevated myocardial
139 infarction (STEMI), or non-ST-elevated myocardial infarction (NSTEMI), or unstable angina
140 pectoris.
141 The definitions of outcomes aimed in this SLR protocol are those defined by the Academic
142 Research Consortium (ARC).[19] Data extraction is stratified according to patient clinical
143 presentation, i.e., ACS *versus* with other CAD.
144
145 **Statistical analysis**
146 The two treatment arms are compared for each endpoint using the risk ratio (RR) defined as *((n*
147 *patients with an event in TiNOS)/(n patients in TiNOS))/((n patients with an event in DES)/(n*
148 *patients in DES))*. As a result, RR > 1 reflects a higher frequency of events in the TiNOS arm
149 than in the DES arm and conversely. Outcomes are analyzed on an intention-to-treat (ITT) basis.
150 The numerator is the number of patients presenting an event and counted in the treatment arm
151 they were randomized to and the denominator is the sample size of the corresponding arm.
152 For each endpoint, individual study RRs are calculated with their 95% confidence interval (CI
153 [,]) and their degree of heterogeneity is determined. If no significant heterogeneity is detected,
154 the pooled RR is calculated with its CI using the M-H method with a fixed-effect model.[16,20,21]
155 In the case of significant heterogeneity, pooling uses the M-H method with a random-effects
156 model. The pooled analysis is stratified according to baseline clinical presentation, ACS *versus*
157 other CAD. One-year and 5-year outcomes are analyzed separately. Sensitivity analysis is
158 performed by iteratively recalculating the pooled RR after removing one eligible RCT. As a
159 result, the impact of each RCT on the pooled RR is estimated. It estimates the impact of

differences in stent generations and the potential risk of indirection related to differences in outcome definitions.

Patient and public involvement

No patient involved.

Results

Overall

Study identification, screening, and selection are described in the PRISMA flowchart (Figure 1). One hundred and eleven references were identified and nine publications with first-hand data about five RCTs are eligible for inclusion in the meta-analysis.

The number of patients with 1-year follow-up data is 1,855 in the TiNOS arm *versus* 1,363 in the DES arm. Those numbers are 783 *versus* 773 patients at 5-year follow-up. Three RCTs enrolled only patients presenting with ACS and two enrolled and analyzed jointly patients presenting with ACS and other CAD. TIDE enrolled 143 patients with ACS (47%) and TITANIC-XV, 112 (64.7%). The baseline characteristics are summarized in Table 1. Funnel plots and Harbord tests did not detect a risk of publication bias concerning any of the endpoints at 1-year follow-up in all CAD (supplemental material).

Four RCTs report or enable to deduct the number of cases of clinically driven TLR, CD, non-fatal recurrent MI, and the composite of CD or any non-fatal MI extended or clinically driven TLR. This results in a modified device-oriented MACE where MI “not clearly attributable to a nontarget vessel” is replaced by any MI. Given fatal MIs are counted as CD, this modification adds non-fatal MI from nontarget vessels.

183 In one RCT (TITANIC-XV), the primary endpoint is estimated from the available data as the
184 sum of CD, any non-fatal MI, and any TLR assuming no overlap between those variables.

185 The risk of bias in individual RCTs is rated moderate or low except for the operator's knowledge
186 of the type of stent used during the intervention in all RCTs.
187 The pooled RRs of all outcomes at 1-year and 5-year follow-up are reported in Table 2 with CIs
188 and sensitivity analyses. Results are reported in all CAD and in the ACS subgroup. Given the 5-
189 year follow-up of patients in the TIDES-ACS trial is ongoing, pooled RRs for 5-year outcomes
190 are interim results.
191 The stratified Forest plots (ACS *versus* other CAD) with heterogeneity analysis show no
192 significant difference in 1-year MACE, CD and between TiNOS and DES, significantly lower
193 rates of non-fatal, MI and ST with TiNOS compared to DES, and a significantly higher rate of
194 TLR with TiNOS (Figure 2 to Figure 6).
195 The stratified shows a much larger number of patients in the ACS subgroup compared to the
196 other CAD subgroup (85.2% *versus* 14.8%). The overall effects are driven by the ACS subgroup.
197 The results of the other CAD subgroup (TIDE and TITANIC-XV) are not interpretable because
198 outcomes in patients with ACS are not reported separately. Therefore, the subsequent steps of
199 this SLR are refocused on RCT about ACS only.
200 **ACS at 1-year follow-up**
201 The pooled RR of MACE is non-significant without significant heterogeneity between studies
202 (Figure 2) and robust to sensitivity analysis (Table 2). The certainty of the evidence is rated high.
203 The pooled RR of CD is not significant, heterogeneity is serious (Figure 3), results are not robust
204 to sensitivity analysis and the certainty of the evidence is rated very low. Similar weaknesses
205 apply to TD.

206

207 The pooled RR of non-fatal MI is significant, without significant heterogeneity between studies
208 (Figure 4) and robust to sensitivity analysis, and the certainty of the evidence is rated moderate.
209 The pooled RR of clinically driven TLR is significant in favor of DES, without significant
210 heterogeneity (Figure 5), but results are not robust to sensitivity analysis, and the certainty of the
211 evidence is rated low.
212 The pooled RR of probable or definite ST is significant in favor of TiNOS, without significant
213 heterogeneity (Figure 6), results are robust to sensitivity analysis and the certainty of the
214 evidence is rated low.
215

216 **Discussion**

217 TIDE and TITANIC-XV enrolled 255 patients with ACS but their data are not reported
218 separately from the other patients. The impact of not including them in the ACS subgroup is
219 limited given they represent 7.9% of all patients with ACS. The modified definition of device-
220 oriented MACE results in including non-fatal MIs from nontarget vessels. One can reasonably
221 assume the index stent does not affect those events. Ninety non-fatal MIs are reported. Assuming
222 half of them are related to nontarget vessels (i.e., 45 cases), proportionality with sample size
223 would lead to 27 fewer cases with TiNOS and 18 with DES, which would result in an RR of 0.19
224 [0.09, 0.42]. The inclusion of nontarget MIs thus results in a dilution that is favorable to DES. If
225 the same numbers cases were removed from the count of MACE, the RR would be 0.98 [0.73,
226 1.30], which would not change the non-inferiority conclusion. The robustness to sensitivity
227 analysis of the pooled RRs of MACE, MI, and ST in ACS, shows that the differences in DES
228 generations, including the elution of paclitaxel and mTOR inhibitors do not significantly change

229 those results. The interim 5-year pooled results will be updated when the final results of TIDES-
230 ACS are published, but the current results are consistent with 1-year outcomes.
231
232 **Conclusions**
233 This systematic literature review shows that titanium-nitride oxide coated-coronary stents and
234 drug-eluting stents have a similar risk of device-oriented major adverse cardiac events at one-
235 year follow-up in patients with an acute coronary syndrome. This result is robust and the level of
236 certainty of the evidence is high. It also shows a lower risk of recurrent myocardial infarction
237 and stent thrombosis with titanium-nitride oxide coated-coronary stents than with drug-eluting
238 stents with a potentially higher risk of target lesion revascularization. Interim five-year pooled
239 outcomes are consistent with one-year outcomes. These results show that the titanium-nitride
240 oxide coated-coronary stents are safe and effective in acute coronary syndrome.
241

242

243 **Table 1 Baseline characteristics**

Study	**Age & prior events**			**Clinical presentation**			**Procedural data & medication**			**Attrition & cross-overs**
Stent		TiNOS	DES		TiNOS	DES		TiNOS	DES	
TITAX-AMI[22,23] [NCT00495664]	Patients n age prior MI prior PCI prior CABG	214 64±11 15% 10% 7%	211 64±11 9% 5% 6%	NSTEMI STEMI	61% 39%	54% 46%	stents in culprit lesion n TSL (mm) post-dilation procedural success DAPT 12-months	1.1±0.3 18.5±6.4 42% 99.5% 31%	1.1±0.4 19.2±7.2 35% 98.1% 65%	LFU 1y TiNOS: 0 DES: 0 5y TiNOS 3 DES: 7
TIDE[24] [NCT00492908]	Patients n age prior MI prior PCI prior CABG	152 65.9±9.0 27.6% 25.7% 7.9%	150 63.4±10.5 28.7% 21.3% 25.3% 2.7%	Stable CAD NSTEMI Unstable angina	57.9% 32.9% 9.2%	47.3% 42.0% 10.7%	stents in culprit lesion n TSL (mm) device success DAPT 12-months	1.28±0.55 19.3±11.1 93.0%	1.17±0.45 19.6±10.0 94.6%	LFU 1y TiNOS: 0 DES: 2 5y : N.R.
TITANIC-XV[25] [NCT01510509]	Patients n age prior MI prior PCI prior CABG	83 66.5±8.8 10.8% 8.4% 2.4%	90 64.5±10.1 15.6% 11.1% 2.2%	NST ACS Deducted other CAD	69.9% 30.1%	60.0% 40.0%	stents in culprit lesion n TSL (mm) stent failure DAPT 12 months	1.1±0.3 18.72±8.20 N.R.	1.1±0.3 21.63±9.65 N.R.	N.R.
BASE-ACS[26,27] [NCT00819923]	patients age prior MI prior PCI prior CABG	417 63±12 13.4% 9.6% 4.8%	410 63±12 9.8% 10.5% 4.1%	NSTEMI STEMI Unstable angina	49.4% 38.8% 11.8%	45.6% 38.8% 15.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT : Aspirin : protocol indefinite, actual N.R. Clopidogrel: protocol 6 months, actual N.R.	1.15±0.38 20.8±9.4 42.2% 0.0%	1.14±0.36 20.6±8.2 43.9% 1.0%	LFU 1y TiNOS: 3 DES: 3 5y TiNOS 29 DES: 28
TIDES-ACS[28,29] [NCT02049229]	Patients n age prior MI prior PCI prior CABG	989 62.7±10. 7.6% 7.0% 0.6%	502 62.6±10.5 9.0% 6.6% 1.2%	NSTEMI STEMI	46.3% 44.9%	45.0% 47.6%	stents in culprit lesion n TSL (mm) post-dilation stent failure DAPT 12-months	1.13±0.38 20.5±7.8 33.0% 0.3% 80.3%	1.14±0.37 20.6±7.2 38.0% 1.0% 86.0%	LFU 1y TiNOS: 7 DES: 4

244

245

Table 2 Pooled outcomes with sensitivity analysis

	M-H fixed effects RR & 95% CI after the removal of:					
Endpoint	**None: all RCTs included**	**TITAX-AMI**	**TIDE**	**TITANIC-XV**	**BASE-ACS**	**TIDES-ACS**
ALL CAD: ACS & Other CAD – 1 year follow-up						
MACE	1.01 [0.81, 1.26]	1.06 [0.83, 1.36]	0.96 [0.75, 1.23]	0.98 [0.78, 1.24]	0.99 [0.76, 1.29]	1.07 [0.82, 1.40]
CD or MI	0.55 [0.39, 0.77]	0.57 [0.39, 0.82]	0.52 [0.36, 0.74]	0.55 [0.39, 0.77]	0.53 [0.36, 0.79]	0.60 [0.40, 0.91]
Non-fatal MI	0.52 [0.36, 0.76]	0.51 [0.33, 0.78]	0.48 [0.31, 0.73]	0.52 [0.35, 0.76]	0.60 [0.38, 0.93]	0.51 [0.32, 0.82]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	0.66 [0.33, 1.31]	0.66 [0.33, 1.31]	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.62 [1.20, 2.18]	1.56 [1.13, 2.15]	1.60 [1.15, 2.24]	1.58 [1.16, 2.14]	1.74 [1.22, 2.47]	1.63 [1.14, 2.33]
Probable or definite ST	0.39 [0.22, 0.69]	0.46 [0.25, 0.84]	0.35 [0.20, 0.64]	0.39 [0.22, 0.69]	0.36 [0.18, 0.72]	0.38 [0.16, 0.87]
Definite ST	0.51 [0.26, 0.99]	0.49 [0.25, 0.97]	0.46 [0.23, 0.92]	0.51 [0.26, 0.99]	0.62 [0.29, 1.36]	0.52 [0.18, 1.44]
TD	0.78 [0.48, 1.27]	0.77 [0.46, 1.32]	0.78 [0.47, 1.27]	0.78 [0.48, 1.27]	0.49 [0.26, 0.95] [b]	1.22 [0.65, 2.28]
ACS only – 1 year follow-up						
MACE	0.93 [0.72, 1.20]	0.97 [0.73, 1.30]	N.A.	N.A.	0.86 [0.63, 1.19]	0.95 [0.68, 1.33]
CD or MI	0.52 [0.36, 0.75]	0.53 [0.35, 0.80]	N.A.	N.A.	0.48 [0.30, 0.75]	0.56 [0.35, 0.90]
Non-fatal MI	0.48 [0.31, 0.73]	0.45 [0.27, 0.74]	N.A.	N.A.	0.55 [0.33, 0.92]	0.44 [0.25, 0.77]
CD	0.66 [0.33, 1.31]	0.77 [0.37, 1.61]	N.A.	N.A.	0.30 [0.11, 0.81]	1.11 [0.43, 2.85]
Clinically driven TLR	1.55 [1.10, 2.19]	1.46 [0.99, 2.15]	N.A.	N.A.	1.69 [1.09, 2.63]	1.53 [0.97, 2.40]
Probable or definite ST	0.35 [0.20, 0.64]	0.42 [0.22, 0.78]	N.A.	N.A.	0.32 [0.15, 0.65]	0.31 [0.12, 0.77]
Definite ST	0.46 [0.23, 0.92]	0.43 [0.21, 0.89]	N.A.	N.A.	0.54 [0.24, 1.24]	0.39 [0.12, 1.25]
TD	0.78 [0.47, 1.27]	0.77 [0.45, 1.32]	N.A.	N.A.	0.47 [0.24, 0.93] [b]	1.23 [0.64, 2.35]
ALL CAD: ACS & Other CAD – 5 year follow-up - Interim Results						
MACE	0.82 [0.66, 1.02]	0.91 [0.70, 1.19]	0.74 [0.58, 0.95] [b]	N.A.	0.83 [0.62, 1.10]	Expected
CD or MI	0.57 [0.42, 0.77]	0.67 [0.46, 0.97]	0.53 [0.38, 0.73]	N.A.	0.53 [0.35, 0.80]	Expected
Non-fatal MI	0.56 [0.39, 0.80]	0.59 [0.37, 0.92]	0.54 [0.37, 0.80]	N.A.	0.57 [0.35, 0.93]	Expected
CD	0.68 [0.39, 1.19]	0.93 [0.47, 1.82]	0.59 [0.31, 1.11]	N.A.	0.55 [0.25, 1.24]	Expected
Clinically driven TLR	1.01 [0.75, 1.35]	1.00 [0.71, 1.42]	0.94 [0.66, 1.32]	N.A.	1.13 [0.77, 1.66]	Expected
Probable or definite ST	0.30 [0.14, 0.61]	0.45 [0.19, 1.05]	0.25 [0.12, 0.55]	N.A.	0.22 [0.07, 0.70]	Expected
Definite ST	0.25 [0.11, 0.55]	0.37 [0.14, 0.99]	0.20 [0.09, 0.49]	N.A.	0.22 [0.07, 0.70]	Expected
TD	1.03 [0.74, 1.45]	1.14 [0.75, 1.73]	0.95 [0.65, 1.37]	N.A.	1.05 [0.65, 1.69]	Expected
ACS only – 5 year follow-up - Interim Results						
MACE [a]	0.74 [0.58, 0.95]	0.81 [0.59, 1.12] [c]	N.A.	N.A.	0.65 [0.44, 0.95] [c]	Expected
CD or MI	0.53 [0.38, 0.73]	0.61 [0.40, 0.95]	N.A.	N.A.	0.42 [0.25, 0.71]	Expected
Non-fatal MI	0.54 [0.37, 0.80]	0.56 [0.33, 0.94] [c]	N.A.	N.A.	0.53 [0.30, 0.94] [c]	Expected
CD	0.59 [0.31, 1.11]	0.83 [0.38, 1.84] [c]	N.A.	N.A.	0.33 [0.11, 1.00] [c]	Expected
Clinically driven TLR	0.94 [0.66, 1.32]	0.88 [0.56, 1.37] [c]	N.A.	N.A.	1.03 [0.60, 1.76] [c]	Expected
Probable or definite ST [a]	0.25 [0.12, 0.55]	0.37 [0.15, 0.93] [c]	N.A.	N.A.	0.13 [0.03, 0.57] [c]	Expected
Definite ST [a]	0.20 [0.09, 0.49]	0.28 [0.09, 0.85] [c]	N.A.	N.A.	0.13 [0.03, 0.57] [c]	Expected
TD	0.95 [0.65, 1.37]	1.02 [0.63, 1.65] [c]	N.A.	N.A.	0.85 [0.48, 1.53] [c]	Expected

[a] sensitivity analysis in ACS at 5-year follow-up results in the RR and confidence intervals of individual RCTs; [b] borderline shift with 3 or fewer RCTs contributing to the pooled estimate; [c] results based on a single-trial; N.A. Not applicable

250 **Supplemental material:**

251 - Details of methods applied in this SLR.

252 - Methods of individual RCTs

253 - Table of the number of patients with events – ITT

254 - Funnel plots and results of Harbord tests.

255 - Summary of risk of bias in individual RCTs

256 - Pooled RR of CD or MI, and TD

257 - GRADE certainty of evidence assessment

258 - PRISMA checklist

259

260 **Contributors**

261 Frederic Daoud (FD): Main reviewer and meta-analyst with LL.

262 Louis Létinier (LL): Main reviewer and meta-analyst with with FD.

263 Nicholas Moore (NM): Third reviewer. Adjudicated disagreements.

264 Pierre Coste (PC): Advised on protocol and analysis.

265 Pasi Karjalainen (PK): Provided additional information about the methods of the individual
266 trials.

267

268

Funding

This work was exclusively funded by the University of Bordeaux and INSERM BPH U1219, Bordeaux, France

Data sharing statement

All data included in this review are published.

References

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Ting H, O'Gara PT, Kushner FG, Ascheim DD, Brindis RG, Casey Jr DE 1 , Chung MK, de Lemos JA, Diercks DB, Fang JC, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011 Dec 6; 124(23):e574-651. doi: 10.1161/CIR.0b013e31823ba622. Epub 2011 Nov 7. Erratum in: Circulation. 2012 Feb 28;125(8):e412. Dosage error in article text. PMID: 22064601.

2. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29; 127(4):e362-425. doi: 10.1161/CIR.0b013e3182742cf6. Epub 2012 Dec 17. Erratum in: Circulation. 2013 Dec 24;128(25):e481. PMID: 23247304.

3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38):2949–3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. Erratum in: Eur Heart J. 2014 Sep 1;35(33):2260-1. PMID: 23996286.

316 4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS,
317 Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine
318 MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members; Society for Cardiovascular
319 Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline
320 for the management of patients with non-ST-elevation acute coronary syndromes: a report of the
321 American College of Cardiology/American Heart Association Task Force on Practice
322 Guidelines. Circulation. 2014; 130(25):2354-2394. doi: 10.1161/CIR.0000000000000133. Epub
323 2014 Sep 23. Erratum in: Circulation. 2014 Dec 23;130(25):e431-2. Dosage error in article text.
324 PMID: 25249586.

325 5. Collet J, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt D, Dendale P, Dorobantu M,
326 Edvardsen T, Folliguet T, Gale C, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis B, Mehilli J,
327 Meliga E, Merkely B, Mueller C, Roffi M, Rutten F, Sibbing D, Siontis G, ESC Scientific
328 Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in
329 patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29; ehaa575.
330 doi: 10.1093/eurheartj/ehaa575. Epub ahead of print. PMID: 32860058.

331 6. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP,
332 Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M,
333 Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017
334 ESC Guidelines for the management of acute myocardial infarction in patients presenting with
335 ST-segment elevation: The Task Force for the management of acute myocardial infarction in
336 patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur
337 Heart J. 2018; 39(2):119-177. doi: 10.1093/eurheartj/ehx393. PMID: 28886621.

338 8. Wessely R, Schömig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting
339 stents: similar but different. J Am Coll Cardiol. 2006; 47(4):708-714. doi:
340 10.1016/j.jacc.2005.09.047. Epub 2006 Jan 26. PMID: 16487832.

341 8. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R,
342 Charles P. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and
343 survival: role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol. 2006; 26(7):1473-
344 1480. doi: 10.1161/01.ATV.0000223866.42883.3b. Epub 2006 Apr 27. PMID: 16645158.

345 9. Yazdani SK, Sheehy A, Pacetti S, Rittlemeyer B, Kolodgie FD, Virmani R. Stent Coating
346 Integrity of Durable and Biodegradable Coated Drug Eluting Stents. J Interv Cardiol. 2016;
347 29(5):483-490. doi: 10.1111/joic.12303. Epub 2016 Jun 10. PMID: 27282892.

348 10. Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS,
349 Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M;
350 PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic
351 and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol. 2019; 73(7):741-754. doi:
352 10.1016/j.jacc.2018.11.048. PMID: 30784667.

353 11. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary
354 Intervention Intern Med. 2020; 59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub
355 2019 Oct 7. PMID: 31588089; PMCID: PMC7028427.

356 12. Windecker S, Mayer I, De Pasquale G, Maier W, Dirsch O, De Groot P, Wu YP, Noll G,
357 Leskosek B, Meier B, Hess OM; Working Group on Novel Surface Coating of Biomedical
358 Devices (SCOL). Stent coating with titanium-nitride-oxide for reduction of neointimal
359 hyperplasia. Circulation. 2001; 104(8):928-933. doi: 10.1161/hc3401.093146. PMID: 11514381.

360 13. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric
361 oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci
362 U S A. 2001; 98(7):4202-4208. doi: 10.1073/pnas.071054698. Epub 2001 Mar 20. PMID:
363 11259671; PMCID: PMC31203.

364 14. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M, Pedrazzini G, Moccetti T,
365 Wenaweser P, Togni M, Tüller D, Zbinden R, Seiler C, Mehilli J, Kastrati A, Meier B, Hess OM.
366 Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for
367 coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20):2617-2622. doi:
368 10.1161/CIRCULATIONAHA.104.486647. Epub 2005 May 9. PMID: 15883209.

369 15. Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for
370 clinical questions. AMIA Annu Symp Proc. 2006; 2006:359-363. PMID: 17238363; PMCID:
371 PMC1839740.

372 16. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions.
373 www.cochrane-handbook.org, version 5.1.0 updated March 2011.

374 17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M,
375 Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews
376 and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
377 BMJ. 2009; 339:b2700. doi: 10.1136/bmj.b2700. PMID: 19622552; PMCID: PMC2714672.

378 18. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading
379 quality of evidence and strength of recommendations. Updated October 2013. The GRADE
380 Working Group, 2013. Available from guidelinedevelopment.org/handbook.

381 19. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y,
382 Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW,
383 Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium.. Standardized
384 End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2
385 Consensus Document.. Eur Heart J. 2018 Jun 14;39(23):2392–2207. doi:
386 10.1093/eurheartj/ehy223.; PMID: 29897428.

387 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-
388 88. doi: 10.1016/0197-2456(86)90046-2. PMID: 3802833.

389 21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect
390 and random-effects models for meta-analysis. Res Synth Methods. 2010; 1(2):97-111. doi:
391 10.1002/jrsm.12. Epub 2010 Nov 21. PMID: 26061376.

392 22. Karjalainen PP, Ylitalo A, Niemelä M, Kervinen K, Mäkikallio T, Pietili M, Sia J,
393 Tuomainen P, Nyman K, Airaksinen KE. Titanium-nitride-oxide coated stents versus paclitaxel-
394 eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX
395 AMI trial. EuroIntervention. 2008; 4(2):234-241. doi: 10.4244/eijv4i2a42. PMID: 19110789.

396 23. Tuomainen PO, Ylitalo A, Niemelä M, Kervinen K, Pietilä M, Sia J, Nyman K, Nammas W,
397 Airaksinen KE, Karjalainen PP. Five-year clinical outcome of titanium-nitride-oxide-coated
398 bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction:
399 long-term follow-up from the TITAX AMI trial. Int J Cardiol. 2013; 168(2):1214-1219. doi:
400 10.1016/j.ijcard.2012.11.060. Epub 2012 Dec 3. PMID: 23218575.

401 24. Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M,
402 Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S.
403 Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary
404 revascularization a randomized controlled trial. JACC Cardiovasc Interv. 2011; 4(6):672-682.
405 doi: 10.1016/j.jcin.2011.02.017. PMID: 21700254.

406 25. López-Mínguez JR, Nogales-Asensio JM, Doncel-Vecino LJ, Merchán-Herrera A, Pomar-
407 Domingo F, Martínez-Romero P, Fernández-Díaz JA, Valdesuso-Aguilar R, Moreu-Burgos J,
408 Díaz-Fernández J; members of the TITANIC XV Working Group. A randomized study to
409 compare bioactive titanium stents and everolimus-eluting stents in diabetic patients (TITANIC
410 XV): 1-year results. Rev Esp Cardiol (Engl Ed). 2014; 67(7):522-530. doi:
411 10.1016/j.rec.2013.10.021. Epub 2014 Apr 3. PMID: 24952391.

412 26. Karjalainen PP, Nammas W, Ylitalo A, de Bruyne B, Lalmand J, de Belder A, Rivero-Crespo
413 F, Kervinen K, Airaksinen JKE. Long-term clinical outcome of titanium-nitride-oxide-coated
414 stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE
415 ACS trial. Int J Cardiol. 2016; 222:275-280. doi: 10.1016/j.ijcard.2016.07.267. Epub 2016 Aug
416 1. PMID: 27497110.

417 27. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F, Romppanen H, Sia J, Lalmand
418 J, de Bruyne B, Debelder A, Carlier M, Nammas W, Ylitalo A, Hess OM; BACE-ACS study
419 investigators. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive
420 stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial.
421 EuroIntervention. 2012; 8(3):306-315. doi: 10.4244/EIJV8I3A49. PMID: 22829506.

422 28. Colkesen EB, Eefting FD, Rensing BJ, Suttorp MJ, Ten Berg JM, Karjalainen PP, Van Der
423 Heyden JA. TIDES-ACS Trial: comparison of titanium-nitride-oxide coated bio-active-stent to
424 the drug (everolimus)-eluting stent in acute coronary syndrome. Study design and objectives.
425 Minerva Cardioangiol. 2015; 63(1):21-29. PMID: 25670057.

426 29. Tonino PAL, Pijls NHJ, Collet C, Nammas W, Van der Heyden J, Romppanen H, Kervinen
427 K, Airaksinen JKE, Sia J, Lalmand J, Frambach P, Penaranda AS, De Bruyne B, Karjalainen PP;
428 TIDES-ACS Study Group. Titanium-Nitride-Oxide-Coated Versus Everolimus-Eluting Stents in
429 Acute Coronary Syndrome: The Randomized TIDES-ACS Trial. JACC Cardiovasc Interv. 2020;
430 13(14):1697-1705. doi: 10.1016/j.jcin.2020.04.021. PMID: 32703593.

431 30. Savović J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of
432 the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus
433 groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;
434 3:37. doi: 10.1186/2046-4053-3-37. PMID: 24731537; PMCID: PMC4022341.

435 31. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ;
436 GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and
437 strength of recommendations. BMJ. 2008; 336(7650):924-926. doi:
438 10.1136/bmj.39489.470347.AD. PMID: 18436948; PMCID: PMC2335261.

439 32. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ,
440 Montori VM, Freyschuss B, Vist G, Jaeschke R, Williams JW Jr, Murad MH, Sinclair D, Falck-
441 Ytter Y, Meerpohl J, Whittington C, Thorlund K, Andrews J, Schünemann HJ. GRADE
442 guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011; 64(12):1283-
443 1293. doi: 10.1016/j.jclinepi.2011.01.012. Epub 2011 Aug 11. PMID: 21839614.

444 33. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster
445 University, 2015 (developed by Evidence Prime, Inc.). Available from https://gdt.gradepro.org

446 34. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential
447 monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997; 18(6):580-593;
448 discussion 661-6. doi: 10.1016/s0197-2456(97)00051-2. PMID: 9408720.

449 35. Seeger P, Gabrielsson A. Applicability of the Cochran Q test and the F test for statistical
450 analysis of dichotomous data for dependent samples. Psychol Bull. 1968; 69(4):269-277. doi:
451 10.1037/h0025667. PMID: 5659656.

452 36. Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses
453 in pain using simulations of individual patient data. Pain. 2000; 85(3):415-424. doi:
454 10.1016/s0304-3959(99)00302-4. PMID: 10781914.

455 37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;
456 21(11):1539-1558. doi: 10.1002/sim.1186. PMID: 12111919.

457 38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
458 analyses. BMJ. 2003; 327(7414):557-560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120;
459 PMCID: PMC192859.

460 39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
461 simple, graphical test. BMJ. 1997; 315(7109):629-634. doi: 10.1136/bmj.315.7109.629. PMID:
462 9310563; PMCID: PMC2127453.

463 40. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998; 316(7124):61-66.
464 doi: 10.1136/bmj.316.7124.61. PMID: 9451274; PMCID: PMC2665334.

465 41. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other
466 biases. In: Egger M, Davey Smith G, Altman DG (eds). Systematic Reviews in Health Care:
467 Meta-Analysis in Context. London: BMJ Publishing Group, 2001:189-208.

468 42. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses
469 of controlled trials with binary endpoints. Stat Med. 2006; 25(20):3443-3457. doi:
470 10.1002/sim.2380. PMID: 16345038.

471

472

473 **Figure 1 PRISMA flow chart**

474 **Figure 2 modified device-oriented MACE 1-year**

475 **Figure 3 CD 1-year**

476 **Figure 4 non-fatal MI 1-year**

477 **Figure 5 clinically driven TLR 1-year**

478 **Figure 6 probable or definite ST 1-year**

479


Identification
Screening
Eligibility
Included
Records identified through database searching
Medline 27, Embase 49, WoS 9, Cochrane 24
n = 109
Additional records identified through other sources
n = 2
Records after n = 52 duplicates removed
n = 59
Records screened
n = 23
Records excluded
n = 36
Full-text articles assessed for eligibility
n = 23
Full-text articles excluded,
repeated work, interim & post hoc analyses
n = 14
Studies included in qualitative synthesis
n = 5 (9 records)
Studies included in meta-analysis
n = 5

MACE 1-year

Study or Subgroup	TiNOS Events	TiNOS Total	DES Events	DES Total	Weight	Risk Ratio M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	22	214	27	211	19.9%	0.80 [0.47, 1.36]	2008
BASE-ACS	40	417	37	410	27.3%	1.06 [0.69, 1.63]	2012
TIDES-ACS	62	989	35	502	33.9%	0.90 [0.60, 1.34]	2020
Subtotal (95% CI)		**1620**		**1123**	**81.1%**	**0.93 [0.72, 1.20]**	
Total events	124		99				
Heterogeneity: Chi² = 0.70, df = 2 (P = 0.71); I² = 0%							
Test for overall effect: Z = 0.55 (P = 0.58)							
Other CAD							
TIDE	27	152	21	150	15.4%	1.27 [0.75, 2.14]	2011
TITANIC-XV	8	83	5	90	3.5%	1.73 [0.59, 5.09]	2011
Subtotal (95% CI)		**235**		**240**	**18.9%**	**1.36 [0.85, 2.17]**	
Total events	35		26				
Heterogeneity: Chi² = 0.26, df = 1 (P = 0.61); I² = 0%							
Test for overall effect: Z = 1.27 (P = 0.21)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**1.01 [0.81, 1.26]**	
Total events	159		125				
Heterogeneity: Chi² = 2.79, df = 4 (P = 0.59); I² = 0%							
Test for overall effect: Z = 0.10 (P = 0.92)							
Test for subgroup differences: Chi² = 1.89, df = 1 (P = 0.17), I² = 47.1%							



CD 1-year

Study or Subgroup	TiNOS Events	TiNOS Total	DES Events	DES Total	Weight	Risk Ratio M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	1	214	4	211	21.6%	0.25 [0.03, 2.19]	2008
BASE-ACS	8	417	4	410	21.6%	1.97 [0.60, 6.48]	2012
TIDES-ACS	5	989	8	502	56.8%	0.32 [0.10, 0.96]	2020
Subtotal (95% CI)		**1620**		**1123**	**100.0%**	**0.66 [0.33, 1.31]**	
Total events	14		16				
Heterogeneity: Chi² = 5.67, df = 2 (P = 0.06); I² = 65%							
Test for overall effect: Z = 1.19 (P = 0.23)							
Other CAD							
TIDE	0	83	0	90		Not estimable	2011
TITANIC-XV	0	152	0	150		Not estimable	2011
Subtotal (95% CI)		**235**		**240**		**Not estimable**	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Total (95% CI)		**1855**		**1363**	**100.00%**	**0.66 [0.33, 1.31]**	
Total events	14		16				
Heterogeneity: Chi² = 5.67, df = 2 (P = 0.06); I² = 65%							
Test for overall effect: Z = 1.19 (P = 0.23)							
Test for subgroup differences: Not applicable							



non-fatal MI 1-year

Study or Subgroup	TiNOS Events	Total	DES Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI	Year
ACS							
TITAX-AMI	8	214	14	211	19.4%	0.56 [0.24, 1.32]	2008
BASE-ACS	9	417	24	410	33.2%	0.37 [0.17, 0.78]	2012
TIDES-ACS	18	989	17	502	31.0%	0.54 [0.28, 1.03]	2020
Subtotal (95% CI)		**1620**		**1123**	**83.5%**	**0.48 [0.31, 0.73]**	
Total events	35		55				
Heterogeneity: Chi² = 0.72, df = 2 (P = 0.70); I² = 0%							
Test for overall effect: Z = 3.41 (P = 0.0006)							
Other CAD							
TIDE	8	152	10	150	13.8%	0.79 [0.32, 1.95]	2011
TITANIC-XV	1	83	2	90	2.6%	0.54 [0.05, 5.87]	2011
Subtotal (95% CI)		**235**		**240**	**16.5%**	**0.75 [0.32, 1.74]**	
Total events	9		12				
Heterogeneity: Chi² = 0.08, df = 1 (P = 0.77); I² = 0%							
Test for overall effect: Z = 0.67 (P = 0.50)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**0.52 [0.36, 0.76]**	
Total events	44		67				
Heterogeneity: Chi² = 1.67, df = 4 (P = 0.80); I² = 0%							
Test for overall effect: Z = 3.37 (P = 0.0007)							
Test for subgroup differences: Chi² = 0.89, df = 1 (P = 0.35), I² = 0%							



clinically driven TLR 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Fixed, 95% CI**	**Year**
ACS							
TITAX-AMI	18	214	9	211	13.4%	1.97 [0.91, 4.29]	2008
BASE-ACS	27	417	20	410	29.8%	1.33 [0.76, 2.33]	2012
TIDES-ACS	53	989	17	502	33.3%	1.58 [0.93, 2.70]	2020
Subtotal (95% CI)		**1620**		**1123**	**76.4%**	**1.55 [1.10, 2.19]**	
Total events	98		46				
Heterogeneity: Chi² = 0.67, df = 2 (P = 0.72); I² = 0%							
Test for overall effect: Z = 2.48 (P = 0.01)							
Other CAD							
TIDE	22	152	13	150	19.3%	1.67 [0.87, 3.19]	2011
TITANIC-XV	7	83	3	90	4.2%	2.53 [0.68, 9.46]	2011
Subtotal (95% CI)		**235**		**240**	**23.6%**	**1.83 [1.02, 3.26]**	
Total events	29		16				
Heterogeneity: Chi² = 0.31, df = 1 (P = 0.58); I² = 0%							
Test for overall effect: Z = 2.03 (P = 0.04)							
Total (95% CI)		**1855**		**1363**	**100.00%**	**1.62 [1.20, 2.18]**	
Total events	127		62				
Heterogeneity: Chi² = 1.18, df = 4 (P = 0.88); I² = 0%							
Test for overall effect: Z = 3.16 (P = 0.002)							
Test for subgroup differences: Chi² = 0.22, df = 1 (P = 0.64), I² = 0%							



probable definite ST 1-year	TiNOS		DES			Risk Ratio	
Study or Subgroup	**Events**	**Total**	**Events**	**Total**	**Weight**	**M-H, Fixed, 95% CI**	**Year**
ACS							
TITAX-AMI	1	214	8	211	21.1%	0.12 [0.02, 0.98]	2008
BASE-ACS	5	417	11	410	29.0%	0.45 [0.16, 1.27]	2012
TIDES-ACS	11	989	14	502	48.6%	0.40 [0.18, 0.87]	2020
Subtotal (95% CI)		**1620**		**1123**	**98.7%**	**0.35 [0.20, 0.64]**	
Total events	17		33				
Heterogeneity: Chi^2 = 1.28, df = 2 (P = 0.53); I² = 0%							
Test for overall effect: Z = 3.41 (P = 0.0006)							
Other CAD							
TITANIC-XV	0	83	0	90		Not estimable	2011
TIDE	1	152	0	150	1.3%	2.96 [0.12, 72.11]	2011
Subtotal (95% CI)		**235**		**240**	**1.3%**	**2.96 [0.12, 72.11]**	
Total events	1		0				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.67 (P = 0.51)							
Total (95% CI)		**1855**		**1363**	**100.0%**	**0.39 [0.22, 0.69]**	
Total events	18		33				
Heterogeneity: Chi² = 2.81, df = 3 (P = 0.42); I² = 0%							
Test for overall effect: Z = 3.23 (P = 0.001)							
Test for subgroup differences: Chi² = 1.64, df = 1 (P = 0.20), I² = 39.1%